Aquestive Therapeutics (AQST) revenue breakdown
By product, Manufacture and supply revenue is the largest at 89% of fiscal 2025 revenue, growing 0% a year over 8 years.
By region, United States is the largest at 66% of fiscal 2025 revenue; Ex-United States grew fastest, 21% a year over 8 years.
Revenue by product
Fiscal years, as Aquestive Therapeutics reports them in its 10-K filings; fiscal 2025 total $45M.
| Products | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| Manufacture and supply revenue | $40M | $37M | $39M | $25M | $35M | $36M | $44M | $40M | $40M | 89% |
| License and royalty revenue | $23M | $25M | $7M | $14M | $5M | $2M | $5M | $15M | $4M | 8% |
| Co-development and research fees | $4M | $5M | $4M | $1M | $2M | $1M | $1M | $2M | $1M | 3% |
| Proprietary product sales, net | — | $228,000 | $3M | $6M | $9M | $8M | — | — | — | — |
| Proprietary product revenue, net | — | — | — | — | — | — | — | $315,000 | -$478,000 | -1% |
Revenue by region
Fiscal years, as Aquestive Therapeutics reports them in its 10-K filings; fiscal 2025 total $45M.
| Regions | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| United States | $64M | $65M | $48M | $41M | $43M | $41M | $37M | $40M | $30M | 66% |
| Ex-United States | $3M | $3M | $4M | $5M | $8M | $7M | $13M | $18M | $15M | 34% |
Questions
Where does Aquestive Therapeutics make its money?
In fiscal 2025, by product: Manufacture and supply revenue $40M, License and royalty revenue $4M, Co-development and research fees $1M, Proprietary product revenue, net -$478,000.
From Aquestive Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.